Abstract: The present invention relates to a pharmaceutical crystal of contezolid acefosamil, a preparation method therefor, and uses thereof. The present invention also relates to a crystal or crystal complex of formula I, wherein R is selected from hydrogen, sodium or a mixture thereof in any ratio.

Abstract: A device and method for measuring amplitude of a scanning mirror are disclosed. The device includes a light source (20) for outputting an optical signal; a diaphragm (21) for modifying size and shape of a light spot of the optical signal output by the light source (20); a scanning mirror retainer for placing a scanning mirror (22) to be measured, the scanning mirror, after being retained, being able to periodically reflect the optical signal; a photoelectric sensor (23) including three or more sensing elements and configured to detect and collect the optical signal reflected by the scanning mirror (22); and a signal acquisition and processing unit (24) for processing a signal collected by the photoelectric sensor (23) to derive an amplitude of the scanning mirror (22). Therefore, it is possible to characterize the scanning mirror (22) before the scanning mirror (22) is used, determining performance of the scanning mirror (22).

Abstract: A device and method for measuring amplitude of a scanning mirror are disclosed. The device includes a light source (20) for outputting an optical signal; a diaphragm (21) for modifying size and shape of a light spot of the optical signal output by the light source (20); a scanning mirror retainer for placing a scanning mirror (22) to be measured, the scanning mirror, after being retained, being able to periodically reflect the optical signal; a photoelectric sensor (23) including three or more sensing elements and configured to detect and collect the optical signal reflected by the scanning mirror (22); and a signal acquisition and processing unit (24) for processing a signal collected by the photoelectric sensor (23) to derive an amplitude of the scanning mirror (22). Therefore, it is possible to characterize the scanning mirror (22) before the scanning mirror (22) is used, determining performance of the scanning mirror (22).

Abstract: The present invention provides antimicrobial polymyxin compounds of the following formula I: or pharmaceutically acceptable salts, hydrates, or solvates thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Abstract: A surgical cutting blade for cutting bone material when the blade is coupled to a hand-held surgical saw includes a distal portion comprising a plurality of cutting teeth, a shank portion adjacent the distal portion, and a proximal portion adjacent the shank portion. The proximal portion may include a longitudinally extending slot having a proximal opening. The slot may be shaped to receive a portion of the surgical saw through the proximal opening. The proximal portion may have a plurality of deflectable fingers respectively separated from a plurality of main body portions by respective gaps. The plurality of deflectable fingers may extend adjacent the longitudinally extending slot, and may deflect into the gaps to increase and decrease a width of a portion of the slot.

Abstract: The present invention provides certain water-soluble O-carbonyl phosphoramidate prodrugs of the following formula I: or pharmaceutically acceptable salts thereof that are therapeutic or antibacterial agents, pharmaceutical compositions containing them, methods for their use, and reagents and methods for preparing these compounds.

Abstract: The present invention provides certain water-soluble O-carbonyl phosphoramidate prodrugs of the following formula I: or pharmaceutically acceptable salts thereof that are therapeutic or antibacterial agents, pharmaceutical compositions containing them, methods for their use, and reagents and methods for preparing these compounds.

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: A surgical cutting blade for cutting bone material when the blade is coupled to a hand-held surgical saw includes a distal portion comprising a plurality of cutting teeth, a shank portion adjacent the distal portion, and a proximal portion adjacent the shank portion. The proximal portion may include a longitudinally extending slot having a proximal opening. The slot may be shaped to receive a portion of the surgical saw through the proximal opening. The proximal portion may have a plurality of deflectable fingers respectively separated from a plurality of main body portions by respective gaps. The plurality of deflectable fingers may extend adjacent the longitudinally extending slot, and may deflect into the gaps to increase and decrease a width of a portion of the slot.

Abstract: A surgical cutting blade for cutting bone material when the blade is coupled to a hand-held surgical saw includes a distal portion comprising a plurality of cutting teeth, a shank portion adjacent the distal portion, and a proximal portion adjacent the shank portion. The proximal portion may include a longitudinally extending slot having a proximal opening. The slot may be shaped to receive a portion of the surgical saw through the proximal opening. The proximal portion may have a plurality of deflectable fingers respectively separated from a plurality of main body portions by respective gaps. The plurality of deflectable fingers may extend adjacent the longitudinally extending slot, and may deflect into the gaps to increase and decrease a width of a portion of the slot.

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: Provided herein are antimicrobial tricyclic boron compounds of the following formula I: or pharmaceutically acceptable salts, complexes, or tautomers thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Abstract: A surgical cutting blade for cutting bone material when the blade is coupled to a hand-held surgical saw includes a distal portion comprising a plurality of cutting teeth, a shank portion adjacent the distal portion, and a proximal portion adjacent the shank portion. The proximal portion may include a longitudinally extending slot having a proximal opening. The slot may be shaped to receive a portion of the surgical saw through the proximal opening. The proximal portion may have a plurality of deflectable fingers respectively separated from a plurality of main body portions by respective gaps. The plurality of deflectable fingers may extend adjacent the longitudinally extending slot, and may deflect into the gaps to increase and decrease a width of a portion of the slot.

Abstract: The present invention belongs to pharmaceutical field. It relates to a novel family of bivalent (?)-meptazinol compounds and/or their salts, as well as the preparation and utilization of the compounds in the treatment of neurodegenerative disorders and dementias such as Alzheimer's Disease (AD). In the present invention, bivalent (?)-meptazinol compounds were synthesized, from the starting material (?)-meptazinol, successively by N-demethylation forming (?)-nor-meptazinol and then by acylation with ?,?-alkanediacyl dihalides or alkylation with ?,?-dihaloalkanes. Results from in vitro cholinesterase inhibiting test and AChE-induced A? aggregation test demonstrated that the bivalent (?)-meptazinol compounds and/or their salts were novel bivalent inhibitors of both AChE and A? aggregation. The most potent compound inhibited both AChE and BChE at nM level, which was 10000 and 1500 times more potent than (?)-MEP hydrochloride, respectively.

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.